Bank Pictet & Cie Europe AG Lowers Holdings in Abbott Laboratories $ABT

Bank Pictet & Cie Europe AG trimmed its position in Abbott Laboratories (NYSE:ABT) by 34.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,559 shares of the healthcare product maker’s stock after selling 16,705 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Abbott Laboratories were worth $2,864,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in ABT. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the fourth quarter worth $25,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $26,000. 75.18% of the stock is currently owned by institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ABT shares. Citigroup boosted their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Wells Fargo & Company raised their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.67.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $116.62 on Friday. The firm has a fifty day moving average of $100.08 and a two-hundred day moving average of $100.05. The firm has a market cap of $201.80 billion, a P/E ratio of 37.74, a P/E/G ratio of 2.21 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.